HLB’s Liver Cancer Combination Receives Another FDA CRL: Clinical Evidence and Manufacturing Review Are Different Questions

원문 링크: WordPress 원문

ENGKOR

A drug can produce encouraging results in a large clinical trial and still fail to win regulatory approval. That is the central point behind the latest news involving HLB, Elevar Therapeutics, and Jiangsu Hengrui Pharmaceuticals.

On July 10, 2026, Hengrui disclosed that the U.S. Food and Drug Administration had issued a Complete Response Letter, or CRL, for the biologics license application covering camrelizumab in combination with apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma. Apatinib is the molecule known as rivoceranib in Elevar’s global development program.

A CRL means the FDA cannot approve the application in its present form. It is not an approval, but it is also not necessarily the end of the program. The applicant must understand and address the deficiencies before deciding whether and when to resubmit.

This case needs especially careful reading because the public disclosure separates two very different questions: what the clinical trial found, and whether the medicines can be manufactured under standards acceptable to the regulator.

What the July 10 disclosure actually says

Hengrui’s exchange filing states that the latest regulatory feedback was mainly related to observations from an FDA current Good Manufacturing Practice, or cGMP, inspection of a production site associated with apatinib. The site underwent an FDA cGMP surveillance inspection in April 2026. Hengrui said it had evaluated the observations and begun preparing corrective measures.

The company also stated that the CRL did not raise issues concerning the product’s clinical-study data, safety, or efficacy. That sentence is important, but its source must remain clear: it is Hengrui’s description of the CRL.

The FDA has not publicly released the CRL itself, and the detailed inspection record and corrective-action plan are not available in the sources reviewed for this article. The public therefore cannot independently assess the exact severity of each observation, whether another inspection will be required, or how long remediation may take.

Hengrui said it would work with the FDA and Elevar Therapeutics to clarify the next filing plan. The announcement also explicitly warns that eventual approval remains uncertain.

Why the timing matters

In a February 2, 2026 exchange filing, Hengrui said the FDA had accepted the resubmitted camrelizumab BLA and set a Prescription Drug User Fee Act target date of July 23, 2026. The new CRL arrived before that target date.

A target review date is not a promise of approval. It is the date by which the FDA aims to complete its review action. That action can be an approval, a CRL, or another regulatory outcome permitted under the review process.

HLB’s June 2026 investor presentation had described two earlier CRLs, in May 2024 and March 2025, followed by completion of the NDA/BLA resubmission in January 2026. The July announcement therefore extends a regulatory path that has already required repeated manufacturing and inspection-related work.

The important public question is not simply how many attempts have occurred. It is what remains unresolved now. Based on the July 10 company disclosure, the current issue centers on observations at an apatinib-related manufacturing site. The detailed scope and the time needed to close those observations remain unknown.

What CARES-310 found

The clinical foundation for the combination comes from CARES-310, an international, randomized, open-label phase 3 study conducted at 95 sites across 13 countries and regions. The trial enrolled 543 patients with unresectable or metastatic hepatocellular carcinoma who had not received previous systemic therapy.

Patients received either camrelizumab plus rivoceranib or sorafenib. In the final analysis published in The Lancet Oncology in 2025, the combination continued to show a survival advantage over sorafenib.

• Median overall survival: 23.8 months with camrelizumab plus rivoceranib, compared with 15.2 months with sorafenib; hazard ratio 0.64.

• Median progression-free survival: 5.6 months versus 3.7 months; hazard ratio 0.54.

• Grade 3 or 4 hypertension: 38% versus 15%.

• Treatment-related serious adverse events: 25% versus 7%.

An overall-survival hazard ratio of 0.64 does not mean that 36% of patients were cured. It describes the relative rate of death over the follow-up period between the two randomized groups. The median figures are easier to picture: half of the patients in the combination group were alive beyond 23.8 months, compared with 15.2 months in the sorafenib group, under the conditions of this trial.

The study also shows why benefit and risk must be read together. Grade 3 or 4 hypertension was more frequent with the combination, and treatment-related serious adverse events were reported in one quarter of patients receiving camrelizumab plus rivoceranib. The authors concluded that the benefit-to-risk profile supported the combination as a potential first-line option, but “potential” is not the same as U.S. marketing authorization.

The study was funded by Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics. That does not invalidate the results, but sponsorship is relevant context when reading any industry-funded clinical trial.

Clinical evidence and manufacturing-quality review shown as separate tracks converging on one regulatory decision

Clinical evidence and manufacturing quality answer different questions

Clinical trials ask whether a treatment benefits patients and what harms occur. Manufacturing review asks whether each dose can be produced consistently, controlled properly, and documented under regulatory standards.

These are separate evaluations, but both are required for approval. A regulator does not approve a drug simply because the efficacy signal is strong. It must also be confident that the commercial product will be made reliably and that the manufacturing system can detect and control problems.

This is why two shortcuts should be avoided.

First, the CRL should not be described as proof that the phase 3 efficacy results failed. The July company filing says the latest feedback did not concern clinical data, safety, or efficacy.

Second, it is too strong to say that manufacturing is “the only remaining problem” or that approval will follow automatically once the site responds. The full CRL is not public, the corrective plan has not been completed publicly, and the FDA has not stated that approval is otherwise guaranteed.

The careful conclusion is narrower: the available clinical evidence remains favorable relative to sorafenib, while the U.S. application remains unapproved because the FDA identified deficiencies that the company describes as manufacturing-site related.

What remains unknown

Several questions cannot be answered from the public documents available on July 10.

• What were the exact cGMP inspection observations?

• How serious does the FDA consider each observation?

• Can written corrective evidence close the issue, or will another on-site inspection be needed?

• When will Hengrui and Elevar decide whether to resubmit?

• How will the coordinated review of the camrelizumab BLA and rivoceranib NDA proceed?

• Will the FDA identify any additional deficiencies during a future review cycle?

Until the companies disclose a concrete remediation and resubmission plan—or the regulator makes more information public—an approval date cannot be estimated responsibly.

The simplest way to read the news

If you remember only one thing, remember this: a positive clinical trial and a successful regulatory review are connected, but they are not the same milestone.

CARES-310 provides randomized phase 3 evidence that camrelizumab plus rivoceranib improved survival compared with sorafenib, with a meaningful safety burden that requires clinical management. The July 10 CRL means that evidence has not yet translated into U.S. approval. According to Hengrui, the latest obstacle is tied mainly to manufacturing-site inspection observations, not to a new rejection of the trial’s efficacy result.

The next meaningful update will not be another broad statement of confidence. It will be a specific account of the inspection remediation, whether reinspection is required, and when a complete resubmission can be made.

This article is for public education about drug development and regulatory review. It is not medical advice, treatment guidance, investment advice, or a recommendation regarding HLB, Elevar, Hengrui, any security, or any product. The FDA CRL itself is not public; descriptions of its contents are based on company disclosures.

References

• Jiangsu Hengrui Pharmaceuticals. “Announcement on Receiving a Complete Response Letter for Camrelizumab for Injection.” HKEX filing, July 10, 2026. www1.hkexnews.hk ↗

• Jiangsu Hengrui Pharmaceuticals. “FDA Acceptance of the Resubmitted Biologics License Application for Camrelizumab for Injection.” HKEX filing, February 2, 2026. www1.hkexnews.hk ↗

• HLB. June 2026 investor-relations presentation. Korea Exchange KIND. kind.krx.co.kr ↗

• Qin S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis. The Lancet Oncology. 2025. PMID: 41308676. pubmed.ncbi.nlm.nih.gov ↗

• ClinicalTrials.gov. CARES-310, NCT03764293. clinicaltrials.gov ↗